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Abstract
Artificial intelligence (AI) is one of the most significant fields of development in the current
digital age. Rapid advancements have raised speculation as to its potential benefits in a wide
range of fields, with healthcare often at the forefront. However, amidst this optimism, appre-
hension and opposition continue to strongly persist. Oft-cited concerns include the threat of
unemployment, harm to the doctor–patient relationship and questions of safety and accuracy.
In this article, we review both the current and future medical applications of AI within the
sub-speciality of cancer genomics.
1. Introduction
The concept of artificial intelligence (AI) is not a new one, but only in recent years has it garnered
the levels of interest seen currently. In the form of consumer technology such as the virtual assis-
tants built into most smartphones, AI has already deeply infiltrated our daily lives. The use of AI
in our healthcare system is only in its primitive stages by comparison. The Topol Review recently
explored how the National Health Service (NHS) can best exploit and adapt to the growing
presence of technologies such as AI (Topol, 2019). Despite now being a regular subject of
media attention, confusion and misunderstanding remain surrounding AI.
Therefore, for clarification, some key definitions are listed in Box 1.
2. Applications of AI in cancer genomics
With an estimated 18.1 million new cancer cases recorded worldwide in 2018 (Ferlay et al.,
2018), the enormous burden placed upon healthcare infrastructure is unsurprising. Any
means of alleviating the wide scope of medical, social and economic challenges would be
welcomed.
In a field such as cancer genomics, there are several procedural levels at which AI could be
incorporated to help do this:
1. Use of AI to present patient data in a way that increases the ease and efficiency of human
interpretation.
2. Use of AI to recognize certain features and patterns, highlight these and suggest a course of
action based upon existing manmade guidelines.
3. Use of AI-based systems that can learn from large volumes of data in order to become
autonomous in their decision-making. In this instance, the input data and outcome are
known but the process by which decisions are reached is opaque.
With consideration to the recommendations proposed by the Topol Review, below we
explore the potential uses of AI in cancer genomics, with reference to the stages in a patient’s
clinical pathway (Figure 1). This includes various real-world examples illustrating the various
levels of complexity as listed above.
2.1. Initial referral and diagnosis of cancer
The usual first step along a cancer patient’s journey is their contact with primary care. General
practitioners (GPs) are responsible for the critical decision as to whether or not a case warrants
referral for urgent investigation. Gathering all of the relevant information and making such
important judgements within a 10-minute appointment is a challenging task for any clinician.
Any potential use of AI in this process is complicated by the diverse and complex nature of
patient data, which are often contained in multiple individual electronic silos within the care
record, or even, indeed, on a piece of paper. The Topol Review argues that fully digitizing and
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integrating these records is necessary for the implementation of
AI, but how can this be achieved? The openEHR Foundation
works to develop and implement the infrastructure of improved
electronic medical records in order to help centralize patient
data and improve continuity of care. However, the more we rely
on technological solutions to NHS data issues, the more many
of us become concerned regarding security. The WannaCry ran-
somware attack in 2017 cost the NHS £92 million and brought
this concern to the fore (Harding, 2018). Clearly, developments
in data protection must match the degree to which we become
reliant on technology.
The Topol Review also proposes that AI will enable us to bene-
fit from improved triage. For example, Babylon Health has already
developed a chatbot tool that claims to do just this by asking ques-
tions about the patient’s symptoms and then forwarding them to
advice or a video call. However, many argue that its claims of
accuracy and superiority over clinicians are unfounded. One pub-
lication concluded that there is limited evidence that Babylon is
better than its human counterparts, and the Care Quality
Commission’s 2017 inspection reported that the company was
failing to provide safe care (Fraser et al., 2018).
Thus, to maximize the information-gathering and pattern-
recognition benefits of AI, which could present the busy GP or
oncologist with a clinically relevant overview of the patient in
front of them to guide assessment, there are still huge challenges
in data collection, collation and presentation that need to be
overcome.
Following a referral, investigations are done to confirm or
exclude a cancer diagnosis. These include biopsies, alongside
histopathological, biochemical and radiological analyses. A pro-
posed strength of AI would be the collation, assessment and pat-
tern recognition of integrated datasets pertaining to these
investigations to speed up and improve the accuracy of cancer
diagnosis.
The Royal College of Pathologists is investing in the development
of digital pathology (https://www.rcpath.org/discover-pathology/
public-affairs/digital-pathology.html) and anticipates the future
incorporation of AI into this. Likewise, radiology is also particularly
ripe for integration of AI, such as through complex imaging pattern
analysis (Hosny et al., 2018). The Swiss start-up SOPHiA Genetics
has developed a radiomics platform that aims to notice features in
radiographic images that are missed by the human eye.
At present, cancer multidisciplinary team meetings contain a
pathologist, radiologist and oncologist interpreting and discussing
their various diagnostic tests. Proponents of AI suggest that the
replacement of three experienced consultants with a single AI sys-
tem may well be cost effective, as well as improving diagnostic
accuracy, but proof of this in clinical practice remains elusive
thus far.
2.2. Somatic and constitutional cancer genome analysis
Genomic analysis generates exceptionally large datasets. Ways of
streamlining the analysis to allow easier recognition of clinically
relevant variation are required, and such technology is already
being used in real-world scenarios. Due to the fact that advances
in genomic technologies generating wide-scale whole-genome
data are a recent event, computational solutions for these analyses
have always existed.
AI use in this type of analysis tends to use machine learning
and pattern recognition to present input data in a format that
lends itself to easier interpretation. The aforementioned
SOPHiA Genetics developed a genetics AI that is the company’s
main platform and that uses knowledge-sharing between hospitals
to help train its algorithms. This can locate and highlight muta-
tions in cancer-linked genes within two hours of uploading raw
genomic data, and 503 hospitals around the world are already
using the technology, including several in the UK under the
NHS (Macauley, 2018).
This optimization of data processing equally serves the interest
of patients. The waiting period following genetic testing is asso-
ciated with anxiety and other distressing psychological symptoms,
which many patients find difficult to cope with (Godino et al.,
2015). Reducing the amount of time that this unpleasant process
takes could help ease its mental toll.
2.3. Acute cancer management
2.3.1. Personalized treatment plans
AI could also improve treatment decisions in the management of
cancer patients. In one study, the time taken for the AI platform
IBM Watson to analyse the genome of a brain cancer patient and
suggest an appropriate treatment plan was compared with that
taken by human experts. The experts took 160 hours, whereas
Box 1. Key definitions of terms relating to artificial intelligence and
cancer genomics.
Intelligence: ‘Goal-directed adaptive behaviour’ (Sternberg, 1982);
that is, a measure of the ability to use one’s cognitive functions to
learn, adapt and maximize the probability of success of a given
action, whether that is solving an equation or socially interacting.
Artificial intelligence: First defined as ‘the science of making
intelligent machines’ (McCarthy, 1959). The aim of artificial
intelligence is to emulate any aspect of intelligence in a way that
either matches or exceeds what is attainable by humans alone.
Robot: ‘A machine which can carry out a complex series of actions
automatically’ (Anon., 2010). Automation is not synonymous with
artificial intelligence: artificial intelligence possesses the capacity
to learn and develop without being explicitly programmed,
whereas automation is dependent on pre-programmed input.
Fig. 1. Areas of potential impact of artificial intelligence and genomics in the clinical
care of a cancer patient.
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Watson took a markedly shorter 10 minutes. Unfortunately,
attempts to implement Watson in US hospitals fell massively
short of expectations. There were reports of its recommendations
providing no additional insight compared with those of the
involved human doctors, and sometimes even including concern-
ing inaccuracies (Loh, 2018). This highlights the importance of
not rushing to introduce a technology without fully understand-
ing its capabilities.
AI could also be integrated earlier on in the treatment process.
For example, cancer researchers at the University of Montreal are
currently using AI algorithms for the process of ‘deep learning’,
which refers to a machine learning technique that teaches compu-
ters to learn by example, to investigate the genetic profile of
cancer cells in acute myeloid leukaemia. This may have the poten-
tial one day to help determine the most appropriate course of
treatment, although it is mostly still in the planning stage
(Lemieux, 2018).
2.3.2. Pursuing artificial empathy
The examples of AI mentioned so far supplement rather than
replace doctors, with a human still having to input the data,
often interpret the output and then relay it to the patient through
conversation. Will the scope of AI grow beyond this in the future?
We all know that medical knowledge is not the only factor that
makes a good doctor, whether real or digital. Empathy is so
integral to medical practice that attempts are constantly made
to analyse and quantify it. In one study, patients with the lowest
levels of trust in their doctors had a treatment adherence rate of
just 17.5% (Pearson & Raeke, 2000). In another, the patients
of doctors who were ranked higher on the Jefferson Scale of
Empathy experienced fewer acute complications that required
hospitalization (Hojat et al., 2013).
The Topol Review argues, however, that AI and robotics are
best used to automate mundane tasks instead, so that the work-
force can focus on the more ‘human’ elements of patient care.
However, could it be feasible that AI will actually be used to emu-
late emotional intelligence and beyond?
One possible avenue of achieving this may be through cogni-
tive developmental robotics, which involves the application of
principles of human development to machines. One aspect of
human empathy that has been applied to artificial intelligence
is that relating to emotional contagion and motor mimicry.
These terms encompass the phenomenon through which
the emotions and behaviours of one individual directly trigger
the same in others, such as wincing in response to observing
someone else in pain (Asada, 2014). To achieve this, AI must
replicate our ability to recognize patterns in people’s behaviour
when they are experiencing different emotions, even when we
are unable to precisely describe the features seen (Mehta et al.,
2018). Pattern recognition from datasets of human expressions
of emotions could perhaps be used to achieve this.
In humans and apes, empathy extends further beyond emo-
tional empathy. We also possess cognitive empathy, which is
the conscious drive to process and understand the emotional
states of those around us. Cognitive empathy is yet to be emulated
by AI and is the biggest barrier to true artificial empathy (Asada,
2014).
2.4. Management of future cancer risk
Screening, prevention and early detection for cancer are both clin-
ically preferable and cost effective (Turnbull et al., 2018). From a
public health perspective, the media can have a large influence on
public attitudes to hereditary cancer risk perception – so much so
that the phenomenon has been termed the ‘Angelina Jolie Effect’,
referring to the surge in enquiries and referrals following the
actress’s decision to undertake BRCA1 testing and a risk-reducing
mastectomy (Evans et al., 2014). However, when the phenomenon
gives rise to inaccurate risk perception amongst the public, it can
lead to patient anxiety and misuse of resources. This was a con-
troversial area that most recently generated mainstream media
debate following the personal reflections of the current UK
Secretary of State for Health and Social Care, Matt Hancock, on
his polygenic risk scores relating to his lifetime risk of prostate
cancer.
2.4.1. Risk prediction
AI can already help risk calculation. Data are put into online algo-
rithms, which rapidly produce a figure indicating a particular risk,
based on data modelling and inbuilt datasets of previous patients.
The prevalence of these risk models is only likely to grow, with the
incorporation of increasingly complex genomic data aiming to
improve accuracy (Kim & Kim, 2018). However, useful as these
tools might be, limitations remain.
Its distinctly non-human nature makes it easy to assume that
AI is objective and unprejudiced. However, biases can be rein-
forced through machine learning if they are present within the
datasets from which the AI learns (Char et al., 2018). One
study found that when their AI was fed large datasets of the
English language written by humans, it learned word associations
from these texts that mirrored societal associations. These ranged
from more innocent patterns, such as flowers being connoted
with pleasantness, to more sinister ones. With the researchers
finding the AI linking European names with more positive asso-
ciations versus certain African ones (Caliskan et al., 2017), it is
easy to visualize how a whole host of problems could arise for
various population demographics in a healthcare setting. For
example, if the inputs used to teach an algorithm are inherently
biased towards the medical risks and needs of one group, then
all other patients are at risk of an unequal standard of care.
Traditionally, information to input into risk models is usually
obtained through taking a history from a patient. Patient under-
standing and comprehension can vary greatly, however.
Clarification often needs to be sought by both parties, such as
for apparent diagnoses of ‘stomach cancer’, which could mean
anything from pancreatic cancer to lung cancer with liver metas-
tases. Effective history taking is a complex process and does not
follow a standard algorithm. Subtle signs may demonstrate that
a patient might be withholding information, but an inability to
pick up on this type of red flag is indeed one of the criticisms
faced by the aforementioned Babylon chatbot.
2.4.2. Risk communication and perception
Inappropriate interpretation of a calculated risk is another poten-
tial limitation of AI. The social, cultural and personal factors that
may affect the significance of a risk for a particular patient cannot
be easily incorporated into currently used algorithms. In addition,
the way risk is presented to a patient has been shown to influence
their risk perception (Keller & Siegrist, 2009). Wolfe et al. (2015)
used a web-based intelligent tutoring system to educate patients
about breast cancer genetics. Whilst they found this to be a cost-
effective way of improving patient comprehension and decision-
making compared with a non-interactive website, they concluded
that this was no substitute for genetic counselling.
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2.5. A threat to jobs?
The potential threat that AI poses against the utility of human
employees is an argument at the forefront of its opposition, and
the field of medicine is no exception to this. The Topol Review
argues that there will be ‘significant changes to the roles and
responsibilities of current NHS staff’ thanks to AI, but what
form could these changes take?
Physical contact is needed to perform any sort of medical pro-
cedure, and even the most intelligent of digital software is, of
course, very obviously not able to do this. However, robots have
been propositioned as the hardware that could be controlled by
AI to make this strange and intangible concept a reality. Most cur-
rent healthcare robots, such as those in laparoscopic surgery, must
be controlled by humans, and others have only a low level of AI
influencing their physical actions. Nonetheless, the Topol Review
anticipates that robots will be developed to exploit more advanced
AI algorithms, enabling them to perform both manual and cogni-
tive tasks.
However, the general public appears less receptive than Topol
to the idea of a robotic coup of medical procedures, with only 23%
of UK adults reporting that they are comfortable with the idea of
intelligent machines performing medical operations (Timson,
2017). The importance of ensuring that the direction AI develop-
ment takes aligns with the desires of the patients and public
cannot be understated, meaning that AI-using robots should be
developed with the end goal of supplementing, rather than
replacing, the work of human professionals. Topol does also rec-
ommend that more employment opportunities should be gener-
ated to help develop these technologies, meaning that AI’s
growing role could actually generate more jobs in the NHS rather
than threaten them.
2.6. Clinical governance
This review highlights the promising scope of innovation and
enterprise in AI as a tool to improve the field of cancer genomics.
Equally, however, issues and limitations that reach beyond the tech-
nology itself continue to persist. These issues must be addressed if
AI is to be successfully integrated into the patient pathway.
The major increase in the use of genetic testing over the past
decade has highlighted the inevitable fact that medical profes-
sionals are not infallible. In a review of one US legal database,
more than 50 cases were identified in which healthcare providers
were sued for failing to appropriately utilize genetic testing
(Lindor & Marchant, 2011).
If a patient were to seek legal action following such an incident
caused by an artificially intelligent machine, then who would be
deemed responsible in this instance? Would it be the doctor
who referred them, the software developer or the AI itself? It is
often the case that the inputs and outputs of an algorithm can
be seen, but the way in which the output was decided cannot.
This is referred to as the ‘black box phenomenon’, and it further
complicates these questions.
Indeed, a solution has not yet been developed, but there are
multiple avenues that the issue of liability could take in such an
instance. There is debate as to what extent an AI platform
could be allocated the status of legal personhood, similar to
how corporations can be allocated rights associated with human
persons. Further, the people who manage the AI could be held
responsible through vicarious liability, in the same way in
which an employer is responsible for their employees’ actions.
Platforms under the spectrum of eHealth in the UK are
included in the classification system of the Medicines and
Healthcare Products Regulatory Agency. However, the growth of
AI is already beginning to expose weaknesses in their framework.
For example, the Babylon chatbot is counted as a Class I medical
device, placing it in the same category as a wheelchair or stetho-
scope. This means that it does not need to pass a conformity
assessment and is under minimal regulation.
3. Conclusion
The use of AI in healthcare continues to expand. Nonetheless, a
dystopian future of clinicians ousted by a workforce of machines
currently appears an unrealistic one. Ranging from data complex-
ity to policy and patient trust, the areas of debate that must be
tackled cannot be understated. Nonetheless, the rapid growth
we are seeing in the development and use of AI is undeniable,
and we must prepare ourselves for the inevitable changes we
will see in our lifetimes. It is only by education, discussion and
adaptation amongst both medical professionals and laypeople
alike that we will best reap the benefits of AI in genomic medicine
for everyone involved.
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